Condition: Multiple Myeloma · Sponsor: Johnson & Johnson Private Limited
The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| M S Ramaiah Medical College and Hospital | Bangalore, India | Recruiting |
| St. Johns Medical College And Hospital | Bengaluru, India | Recruiting |
| Post Graduate Institute of Medical Education And Research PGIMER | Chandigarh, India | Recruiting |
| Bhagwan Mahaveer Cancer Hospital & Research Centre | Jaipur, India | Recruiting |
| Tata Medical Center | Kolkata, India | Recruiting |
| Tata Memorial Hospital | Mumbai, India | Recruiting |
| KIMS-Kingsway Hospitals | Nagpur, India | Recruiting |
| All India Institute of Medical Sciences | New Delhi, India | Recruiting |
| Rajiv Gandhi Cancer Institute & Research Centre | New Delhi, India | Recruiting |
| Jawaharlal Institute of Postgraduate Medical Education and Research | Puducherry, India | Recruiting |
| Christian Medical College | Ratnagiri Kilminnal, India | Recruiting |
| Regional Cancer Centre | Thiruvananthapuram, India | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07030517